The efficacy of low-dose intranasal scopolamine for motion sickness

Aviation Space and Environmental Medicine

Volumn 81, Issue 4, 2010, Pages 405-412

  Simmons, Rita G ^a   Phillips, Jeffrey B ^a   Lojewski, Renee A ^a   Wang, Zuwei ^b   Boyd, Jason L ^c   Putcha, Lakshmi ^d  

^a Aerospace Medical Research Laboratory   (United States)

^b WYLE LABORATORIES   (United States)

^c UNIVERSITIES SPACE RESEARCH ASSOCIATION   (United States)

^d NASA JOHNSON SPACE CENTER   (United States)

Author keywords

Clinical trials; Coriolis cross coupling; Motion sickness

Indexed keywords

EID: 77950681908     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ahmed S, Sileno AP, deMeireles JC, Dua R, Pimplaskar HK, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res 2000; 17:974-977
2. Brown JH, Taylor P. Muscarinic receptor agonists and antago- nists. In: Hardman JG, Limbird LE, Gillman AG, eds. The pharmacologic basis of therapeutics, 10th ed. Europe: McGrawHill Education; 2001:148-153
3. Buckey JC, Alvarenga DL, Mackenzie TA, Wang Z, Das H, et al. Intranasal scopolamine for motion sickness. [Abstract.] Aviat Space Environ Med 2008; 79:306.
4. Chien YW, Su KSE, Chang S, eds. Nasal systemic drug delivery. New York: Informa Healthcare; 2008:39-78.
5. Chinn HI, Hyde RW, Milch LJ. Prevention and treatment of motion sickness by intranasal medication. Proc Soc Exp Biol Med 1955; 90:666-669
6. Elsmore TF, Reeves DL. ANAM readiness evaluation system (ARES): user's guide. Chula Vista, CA-. Activity Research Services; 2004.
7. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker; 1982.
8. Golding JF. A short questionnaire to assess motion sickness susceptibility (MSSQ-short): normative values, reliability, and predictive validity. Proceedings of the XXXVII International Symposium of Otoneurology; 2003 May 29-31; Saint-Entienne, France; 2003.
9. Golding JF. Motion sickness susceptibility. Auton Neurosci 2006; 129:67-76.
10. Heer M, Paloski WH. Space motion sickness: incidence, etiology, and countermeasures. Auton Neurosci 2006; 129:77-79 (Pubitemid 44472636)
11. Hixon WC, Niven JI. Directional differences in visual acuity during vertical nystagmus. Pensacola, FL: Naval Aerospace Medical Institute; 1969. Report No. NAMI-1079; NASA Order No. R-93.
12. Hutchins CW Jr, Kennedy RS. Clinical problems in aviation medicine. Relationship between past history of motion sickness and attrition from flight training. Aerosp Med 1965; 36:984-987
13. Kaida K, Takahashi M, Akerstedt T, Nakata A, Otsuka Y, et al. Validation of the Karolinska Sleepiness Scale against performance and EEG variables. Clin Neurophysiol 2006; 117: 1574-1581 (Pubitemid 43947698)
14. Kennedy RS, Odenheimer RC, Baltzley DR, Dunlap WP, Wood CD. Differential effects of scopolamine and amphetamine on microcomputer-based performance tests. Aviat Space Environ Med 1990; 61:615-621 (Pubitemid 20227920)
15. Klöcker N, Hanschke W, Toussaint S, Verse T. Scopolamine nasal spray in motion sickness: a randomized, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci 2001; 13:227-232 (Pubitemid 32288792)
16. Koller G, Satzger W, Adam M, Wagner M, Kathmann N, et al. Effects of scopolamine on matching to sample paradigm and related tests in human subjects. Neuropsychobiology 2003; 48:87-94. (Pubitemid 37176873)
17. Nachům Z, Shahal B, Shupak A, Spitzer O, Gonen A, et al. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001; 296:121-123 (Pubitemid 32015069)
18. Parrott AC. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 1989; 60:1-9.
19. Putcha L, Cintron NM, Tsui J Vanderploeg JM, Kramer WG. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm Res 1989; 6:481-485 (Pubitemid 19182184)
20. Putcha L, Tietze KJ, Bourne DW, Parise CM, Hunter RP, Cintron NM. Bioavailability of intranasal scopolamine in normal subjects. J Pharm Sci 1996; 85:899-902. (Pubitemid 26271363)
21. Simmons RG, Phillips JB, Lojewski RA. Efficacy of intranasal scopolamine gel for motion sickness treatment in aviation candidates. Pensacola, FL: Naval Aerospace Medical Research Laboratory; 2009. DTIC Technical Report ADA503148.
22. Simmons RG, Phillips JB, Lojewski RA, Lawson BD. A comparison of intranasal and oral scopolamine for motion sickness prevention in military personnel. Pensacola, FL: Naval Aerospace Medical Research Laboratory; 2008. DTIC Technical Report ADA488231.
23. 3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27:147-157
24. Tonndorf J, Hyde RW, Chinn HI, Lett JE. Absorption from nasal mucous membrane: systemic effect of hyoscine following intranasal administration. Ann Otol Rhinol Laryngol 1953; 62:630-641
25. Wood CD, Graybiel A. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions. Aerosp Med 1968; 39:1341-1344